The High Price of Success

The High Price of Success

October 2, 2004

News

Article

Pharmaceutical TechnologyPharmaceutical Technology-10-02-2004

Volume 28

Issue 10

Beyond the inevitable debate over profit margins, the increasing range and effectiveness of modern medicine leave us with one core issue: the high price of success.

External Link - article-142142.pdf

Articles in this issue

A Novel Freeze Pelletization Technique for Preparing Matix Pellets

Aseptic Processing: A Review of Current Industry Practice

Can Inserts Be Improved?

Analysis of a Kneading Process to Evaluate Drug Substance-Cyclodextrin Complexation

Drug Development Linked More Closely to Diagnostics

Preparation and In Vitro Characterization of Self-Nanoemulsified Drug Delivery Systems of Coenzyme Q10 Using Chiral Essential Oil Components

In The Spotlight-October 2004

October 2004

Visible-Residue Limit for Cleaning Validation and its Potential Application in Pharmaceutical Research Facility

The High Price of Success

Pharma Company Investment in Parenteral Manufacturing Capacity Picking Up

USP General Notices and General Test Chapters: Interpretations and Misinterpretations

Breaking the Barrier: Advances in Transdermal Technology

Related Content

mainz,Rhineland-Palatinate /germany - 16 07 2022: the biontech company building and flags in mainz germany | Image Credit: © Tobias Arhelger - stock.adobe.com

CureVac to Be Acquired by BioNTech in $1.25B Deal to Advance mRNA Cancer Therapies

Christopher Cole

June 12th 2025

Article

The acquisition boosts BioNTech’s mRNA design and manufacturing capabilities, accelerating development of next-gen cancer immunotherapies.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol

April 30th 2024

Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Darmstadt, Germany - November 10, 2021: A building at the headquarters of science and technology company Merck KGaA. | Image Credit: © Anne Czichos - stock.adobe.com

MilliporeSigma and Simtra Launch Five-Year Agreement for Drug Substance, Drug Manufacturing Services

Patrick Lavery

June 11th 2025

Article

The agreement has been designed to offer a turnkey service to companies seeking faster time to market.

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Jill Murphy

November 14th 2023

Podcast

In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.

China’s NMPA Approves Merck KGaA Treatment for Tenosynovial Giant Cell Tumor

Patrick Lavery

June 10th 2025

Article

NMPA’s Center for Drug Evaluation accepted Merck KGaA’s application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with TGCTs that require systemic treatment.